Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

943 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
Fernández-Nogueira P, Mancino M, Fuster G, López-Plana A, Jauregui P, Almendro V, Enreig E, Menéndez S, Rojo F, Noguera-Castells A, Bill A, Gaither LA, Serrano L, Recalde-Percaz L, Moragas N, Alonso R, Ametller E, Rovira A, Lluch A, Albanell J, Gascon P, Bragado P. Fernández-Nogueira P, et al. Among authors: serrano l. Clin Cancer Res. 2020 Mar 15;26(6):1432-1448. doi: 10.1158/1078-0432.CCR-19-0353. Epub 2019 Nov 7. Clin Cancer Res. 2020. PMID: 31699826
Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma.
Rojo F, González-Pérez A, Furriol J, Nicolau MJ, Ferrer J, Burgués O, Sabbaghi M, González-Navarrete I, Cristobal I, Serrano L, Zazo S, Madoz J, Servitja S, Tusquets I, Albanell J, Lluch A, Rovira A, Eroles P. Rojo F, et al. Among authors: serrano l. Br J Cancer. 2016 Jul 26;115(3):322-31. doi: 10.1038/bjc.2016.204. Epub 2016 Jul 12. Br J Cancer. 2016. PMID: 27404455 Free PMC article.
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.
Sabbaghi M, Gil-Gómez G, Guardia C, Servitja S, Arpí O, García-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martínez-García M, Zazo S, Chamizo C, González-Alonso P, Madoz-Gúrpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A, Albanell J. Sabbaghi M, et al. Among authors: serrano l. Clin Cancer Res. 2017 Nov 15;23(22):7006-7019. doi: 10.1158/1078-0432.CCR-17-0696. Epub 2017 Aug 18. Clin Cancer Res. 2017. PMID: 28821558
High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer.
Muntasell A, Servitja S, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, López-Botet M. Muntasell A, et al. Among authors: serrano l. Cancer Immunol Res. 2019 Aug;7(8):1280-1292. doi: 10.1158/2326-6066.CIR-18-0896. Epub 2019 Jun 12. Cancer Immunol Res. 2019. PMID: 31189644
Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19).
Mancebo G, Solé-Sedeño JM, Membrive I, Taus A, Castells M, Serrano L, Carreras R, Miralpeix E. Mancebo G, et al. Among authors: serrano l. Int J Gynecol Cancer. 2021 Jun;31(6):914-919. doi: 10.1136/ijgc-2020-001942. Epub 2020 Oct 5. Int J Gynecol Cancer. 2021. PMID: 33020205 Review.
Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case-control study.
Posso M, Corominas JM, Serrano L, Román M, Torá-Rocamora I, Domingo L, Romero A, Quintana MJ, Vernet-Tomas M, Baré M, Vidal C, Sánchez M, Saladié F, Natal C, Ferrer J, Servitja S, Sala M, Castells X; BELE Study Group. Posso M, et al. Among authors: serrano l. Cancer Med. 2017 Jun;6(6):1482-1489. doi: 10.1002/cam4.1080. Epub 2017 May 4. Cancer Med. 2017. PMID: 28470951 Free PMC article.
ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression.
Hernández-Llodrà S, Juanpere N, de Muga S, Lorenzo M, Gil J, Font-Tello A, Agell L, Albero-González R, Segalés L, Merino J, Serrano L, Fumadó L, Cecchini L, Lloreta-Trull J. Hernández-Llodrà S, et al. Among authors: serrano l. Oncotarget. 2017 May 26;8(43):74106-74118. doi: 10.18632/oncotarget.18266. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088771 Free PMC article.
943 results